Literature DB >> 17562826

Predicting short-term disability in multiple sclerosis.

S A Gauthier1, M Mandel, C R G Guttmann, B I Glanz, S J Khoury, R A Betensky, H L Weiner.   

Abstract

OBJECTIVE: To develop covariate specific short-term disability curves to demonstrate the probability of progressing by Expanded Disability Status Scale (EDSS) at semiannual visits.
METHODS: Semiannual EDSS scores were prospectively collected in 218 relapsing-remitting (RR) and clinically isolated syndrome (CIS) patients as part of the Comprehensive Longitudinal Investigation of Multiple Sclerosis at the Brigham and Women's Hospital (CLIMB) study. Baseline brain parenchymal fraction (BPF) and T2 lesion volume were available on 205 patients. A partial proportional odds model determined the influence of covariates on the change in EDSS score at subsequent visits. A discrete second order Markov transitional model was fit and generated a probability matrix for each subject; the 6-month probabilities of EDSS change were graphically represented.
RESULTS: The univariate analysis demonstrated the lowest baseline BPF quartile (OR 1.99; p = 0.0203) and the highest T2 lesion volume quartile (OR 2.19; p = 0.0130) were associated with progression in EDSS. Covariate specific disability curves demonstrated the effect of BPF and T2 lesion volume on short-term progression. In subjects with a 6-month EDSS of 2, the probability of a sustained progression of an EDSS of 3 within 3 years was 0.277 for a subject with low BPF and a high T2 lesion volume vs 0.055 for a subject with high BPF and a low T2 lesion volume.
CONCLUSIONS: Markov transitional models allow for the comparison of covariate specific short-term disability changes among groups of patients with multiple sclerosis.

Entities:  

Mesh:

Year:  2007        PMID: 17562826     DOI: 10.1212/01.wnl.0000264890.97479.b1

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  26 in total

1.  Simultaneous Confidence Intervals Based on the Percentile Bootstrap Approach.

Authors:  Micha Mandel; Rebecca A Betensky
Journal:  Comput Stat Data Anal       Date:  2008-01-10       Impact factor: 1.681

Review 2.  MRI in multiple sclerosis: what's inside the toolbox?

Authors:  Mohit Neema; James Stankiewicz; Ashish Arora; Zachary D Guss; Rohit Bakshi
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

Review 3.  Defining Disease Activity and Response to Therapy in MS.

Authors:  Ulrike W Kaunzner; Mais Al-Kawaz; Susan A Gauthier
Journal:  Curr Treat Options Neurol       Date:  2017-05       Impact factor: 3.598

Review 4.  MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.

Authors:  Ulrike W Kaunzner; Susan A Gauthier
Journal:  Ther Adv Neurol Disord       Date:  2017-05-12       Impact factor: 6.570

Review 5.  Brain MRI atrophy quantification in MS: From methods to clinical application.

Authors:  Maria A Rocca; Marco Battaglini; Ralph H B Benedict; Nicola De Stefano; Jeroen J G Geurts; Roland G Henry; Mark A Horsfield; Mark Jenkinson; Elisabetta Pagani; Massimo Filippi
Journal:  Neurology       Date:  2016-12-16       Impact factor: 9.910

6.  Possible clinical outcome measures for clinical trials in patients with multiple sclerosis.

Authors:  Myla D Goldman; Robert W Motl; Richard A Rudick
Journal:  Ther Adv Neurol Disord       Date:  2010-07       Impact factor: 6.570

7.  Estimating time to disease progression comparing transition models and survival methods--an analysis of multiple sclerosis data.

Authors:  Micha Mandel; Francois Mercier; Benjamin Eckert; Peter Chin; Rebecca A Betensky
Journal:  Biometrics       Date:  2013-02-14       Impact factor: 2.571

8.  Sensorimotor dysfunction in multiple sclerosis and column-specific magnetization transfer-imaging abnormalities in the spinal cord.

Authors:  Kathleen M Zackowski; Seth A Smith; Daniel S Reich; Eliza Gordon-Lipkin; BettyAnn A Chodkowski; Divya R Sambandan; Michael Shteyman; Amy J Bastian; Peter C van Zijl; Peter A Calabresi
Journal:  Brain       Date:  2009-03-18       Impact factor: 13.501

9.  Quantitative risk-benefit analysis of natalizumab.

Authors:  J P Thompson; K Noyes; E R Dorsey; S R Schwid; R G Holloway
Journal:  Neurology       Date:  2008-07-29       Impact factor: 9.910

10.  Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS. A large scale, short-term follow-up study.

Authors:  Sarlota Mesaros; Maria A Rocca; Maria P Sormani; Arnaud Charil; Giancarlo Comi; Massimo Filippi
Journal:  J Neurol       Date:  2008-07-03       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.